Navigation Links
Amgen Announces 2012 Third Quarter Dividend
Date:7/19/2012

both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain;
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014   Sequenom, Inc. (NASDAQ: ... provides innovative genetic analysis solutions, and Mayo Medical ... services in the United States , ... patents and applications. "We have great appreciation ... care, and we welcome the opportunity to partner with ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... team of researchers has created a new way ... textures. These surfaces, made by self-assembly of carbon ... including controllable mechanical stiffness and strength, or ... direction. , "We have demonstrated that mechanical forces ... complex three-dimensional microstructures, and that we can independently ...
(Date:7/29/2014)... 29, 2014  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: IPXL).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... July 29, 2014, Impax Laboratories, Inc. (the "Company") issued ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... Mass., Dec. 15 Repligen Corporation (Nasdaq: RGEN ) ... funding to support the ongoing development of new treatments for ... grant will support the completion of preclinical GLP toxicology testing ... trials. Support from the MDA not only provides important ...
... , , , , , , , ... Board : AEMD) announced today that Dr. Jeff Schorey and Dr. ... Exosome Sciences, Inc. (ESI). Both Dr. Schorey and Dr. Comper are ... of Aethlon Medical, was recently formed to leverage the discovery that ...
... , , PLYMOUTH, Minn., Dec. 15 The Mosaic ... quarter fiscal year 2010 earnings results and financial tables on Tuesday, ... York Stock Exchange. Results will be available on Mosaic,s website ... call with presentation slides on Wednesday, January 6, 2010, to discuss ...
Cached Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2
(Date:7/28/2014)... have pinpointed a mechanism in part of the brain that ... it to both type 1 and type 2 diabetes. The ... Proceedings of the National Academies of Sciences . , ... a part of the hypothalamus known as the ventromedial nucleus ... glucose levels in the blood," said lead author Sabrina Diano, ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... St. Jude Children,s Research Hospital study found that 73 ... doubled their risk of developing metabolic syndrome and related ... The results appear in the current issue of the ... the 1,598 adult survivors of childhood cancer in the ... risk factors like high blood pressure, abdominal obesity, elevated ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... Hunting for meat in the African rainforests has halved the ... consequences. The decline in the number of primates causes a ... this leads to a reduction in the numbers of important ... shown in new research from Lund University in Sweden. ...
... 2013 - Elsevier, a world-leading provider of scientific, technical ... announce the launch of Wound Medicine The ... and Applications . Published in print and ... is devoted to the clinical, scientific and health economics ...
... to determine mercury exposure from dental amalgam fillings may ... from fillings, according to University of Michigan researchers. ... vapor into the mouth. But both the amount of ... presents a significant health risk remain controversial. Public ...
Cached Biology News:Hunting for meat impacts on rainforest 2Elsevier announces the launch of a new journal: Wound Medicine 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
...
Biology Products: